An edible berry with one of the densest plant-pigment loads found in food. The most consistent measured effects are on the blood vessels and on the body's own antioxidant enzymes. The evidence base is real but thin, inconsistent, and largely industry-funded. Main costs are practical: stomach complaints from juice, blocked iron uptake, mild blood thinning. Inexpensive, and directly measurable. (Full Review)
| Marker | Target | Why |
|---|---|---|
| LDL cholesterol | 70–100 mg/dL | Primary lipid endpoint in chokeberry trials |
| Apolipoprotein B | 60–80 mg/dL | Tracks particle number, which lipid trials often miss |
| High-sensitivity C-reactive protein | Below 1.0 mg/L | The marker chokeberry moved most consistently |
| Fasting glucose | 75–90 mg/dL | Chokeberry raised it in under-50s in subgroup analysis |
| HbA1c | 4.8–5.4% | Confirms whether any glucose shift is real or transient |
| Ferritin | 50–150 ng/mL | The most plausible slow harm from daily polyphenol intake |
| Transferrin saturation | 25–35% | Distinguishes true iron shortage from inflammation-driven low ferritin |
| Haemoglobin | 13.5–15.5 g/dL (women), 14.0–16.5 g/dL (men) | Catches functional consequence of reduced iron absorption |
| Home systolic/diastolic blood pressure | 110–120 / 70–80 mmHg | Both a target endpoint and an additive-hypotension safety check |
| INR (warfarin users only) | 2.0–3.0, or the range set by the prescriber | Detects additive anticoagulant effect |
| 24-hour urinary oxalate (stone formers only) | Below 40 mg/day | Chokeberry adds dietary oxalate of unmeasured magnitude |
Cadence: Blood pressure twice weekly through the first month, then monthly; the lipid, inflammation, and glucose panel repeated at 12 weeks and again at 6–12 months; ferritin at 6 months, earlier in menstruating women. Weekly INR for the first month if anticoagulated, then monthly.